(Q46566077)

23 December 2017

title

Targeting angiogenesis in pancreatic cancer (English)

1 reference

23 December 2017

author name string

Philip A Philip

series ordinal

1

1 reference

23 December 2017

language of work or name

English

0 references

publication date

29 May 2008

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

371

1 reference

23 December 2017

issue

9630

1 reference

23 December 2017

page(s)

2062-2064

1 reference

23 December 2017

Pancreatic cancer microenvironment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

VEGF-RII influences the prognosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Transcriptional network governing the angiogenic switch in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960770-9

7 January 2021

10.1016/S0140-6736(08)60770-9

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017